| What it is |
Atomoxetine is a selective norepinephrine reuptake inhibitor (NRI). It’s the only non‑stimulant medication approved by the FDA for treating attention‑deficit/hyperactivity disorder (ADHD). |
| Primary use |
ADHD in children, adolescents, and adults. It can also be prescribed off‑label for conditions such as anxiety or certain types of depression, but that’s less common. |
| How it works |
By blocking the reuptake of norepinephrine, atomoxetine increases the concentration of this neurotransmitter in the synaptic cleft. The heightened norepinephrine signaling improves attention, impulse control, and executive function over time. |
| Typical dosing |
• Children 6–12 y: 0.5 mg/kg/day (max 40 mg/day), titrated up to 1 mg/kg/day (max 80 mg/day) over 2–3 weeks.
• Adolescents 13–17 y: 0.5 mg/kg/day, titrated to 1 mg/kg/day.
• Adults: Start 20 mg once daily (or 40 mg if you’re a fast metabolizer), titrate up to 80–100 mg/day as tolerated.
Take in the morning; if you miss a dose, skip it – don’t double‑dose. |
| Onset & duration |
Effects may take 1–2 weeks to fully manifest. Peak concentration in plasma is reached about 4–6 hours after ingestion. It’s not a “quick fix” like stimulants; rather, it builds up gradually. |
| Common side‑effects |
• Gastro‑intestinal (nausea, vomiting, decreased appetite)
• Fatigue, headache, dizziness
• Mood swings or irritability (especially when first starting)
• Dry mouth, increased heart rate (rare)
• In some people, anxiety or agitation may flare initially.
Most side‑effects ease within a few days to a few weeks. |
| Less common but serious |
• Elevated blood pressure or heart rate (rare) – monitor if you have a cardiovascular history.
• Suicidal ideation or worsening mood in children/adolescents (report promptly).
• Liver injury (extremely rare) – watch for jaundice, dark urine. |
| Drug interactions |
• MAO inhibitors (or within 14 days of an MAOI) – avoid.
• Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine, certain anti‑arrhythmics) can raise atomoxetine levels, increasing side‑effect risk.
• Strong CYP2D6 inducers (e.g., carbamazepine, rifampin) may lower its effectiveness.
• Other stimulants or sympathomimetics (e.g., amphetamines, epinephrine) can add to cardiovascular effects.
• Beta‑blockers or antihypertensives – monitor BP and HR. |
| Contraindications |
• Known hypersensitivity to atomoxetine or any excipients.
• Severe cardiovascular disease (e.g., uncontrolled hypertension, arrhythmias).
• Children or adults with a history of liver disease that impairs drug metabolism (rare). |
| Pregnancy / Breastfeeding |
Category C. Limited data suggest potential fetal harm; use only if benefits outweigh risks. Breastfeeding is usually discouraged, as the drug can be excreted in milk. Discuss with your provider. |
| Special populations |
• CYP2D6 poor metabolizers (about 5–10 % of people) may need lower doses, as the drug stays longer in their system.
• Elderly – no formal age‑specific dose change, but monitor for cardiovascular side‑effects. |
| Things to keep in mind |
1. Adherence – missing a dose can diminish benefit. 2. Behavioral therapy – atomoxetine works best as part of a multimodal treatment plan that includes behavioral strategies. 3. Side‑effect monitoring – track appetite, weight, mood, and BP/HR at the first few visits. |
| FAQs |
• Can it replace stimulants? Yes, for people who don’t tolerate stimulants or prefer a non‑stimulant. 4 weeks to 3 months for a full assessment.
• Will it make me sleepy? Not usually; some people feel calm, but it’s not sedating.
• How soon can I expect improvement? Noticeable change often after 2–3 weeks, full benefit after 6–8 weeks. |